Astemizole

This classification denotes a histamine-1 receptor antagonist with the molecular formula C28H31FN4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7HU6337315, chemically known as 1h-benzimidazol-2-amine, 1-((4-fluorophenyl)methyl)-n-(1-(2-(4-methoxyphenyl)ethyl)-4-piperidinyl)- but generally known as astemizole, which bears US NIH Compound Identifier 2247. European Medicines Agency schedules Astemizole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05586MIG. The term ASTEMIZOLE is an International Non-Proprietary Name. World Health Organization schedules astemizole in its Anatomical Therapeutic Chemical (ATC) Classification. ASTEMIZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule astemizole under HS 29333999 and SITC 51574. As of Q4 2014, ASTEMIZOLE remains the US FDA Preferred Term for this commodity. Astemizole bears US NLM identifiers UMLS ID C0699606 and NCI Concept Code C28834. SMILES: FC1CCC(CN2C(NC3CCN(CC3)CCC3CCC(OC)CC3)NC3C2CCCC3)CC1.